Your browser doesn't support javascript.
IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
Decru, Bram; Van Elslande, Jan; Steels, Sophie; Van Pottelbergh, Gijs; Godderis, Lode; Van Holm, Bram; Bossuyt, Xavier; Van Weyenbergh, Johan; Maes, Piet; Vermeersch, Pieter.
  • Decru B; University Hospitals Leuven, Clinical Department of Laboratory Medicine and National Reference Center for Respiratory Pathogens, Leuven, Belgium.
  • Van Elslande J; University Hospitals Leuven, Clinical Department of Laboratory Medicine and National Reference Center for Respiratory Pathogens, Leuven, Belgium.
  • Steels S; University Hospitals Leuven, Clinical Department of Laboratory Medicine and National Reference Center for Respiratory Pathogens, Leuven, Belgium.
  • Van Pottelbergh G; Academic Centre of General Practice, KU Leuven, Leuven, Belgium.
  • Godderis L; Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
  • Van Holm B; Academic Centre of General Practice, KU Leuven, Leuven, Belgium.
  • Bossuyt X; Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
  • Van Weyenbergh J; Environment and Health, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
  • Maes P; Group IDEWE, External Service for Prevention and Protection at Work, Heverlee, Belgium.
  • Vermeersch P; Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Front Immunol ; 13: 909910, 2022.
Article in English | MEDLINE | ID: covidwho-2163010
ABSTRACT

Background:

IgG anti-spike (S) antibodies arise after SARS-CoV-2 infection as well as vaccination. Levels of IgG anti-S are linked to neutralizing antibody titers and protection against (re)infection.

Methods:

We measured IgG anti-S and surrogate neutralizing antibody kinetics against Wild Type (WT) and 4 Variants of Concern (VOC) in health care workers (HCW) 3 and 10 months after natural infection ("infection", n=83) or vaccination (2 doses of BNT162b2) with ("hybrid immunity", n=17) or without prior SARS-CoV-2 infection ("vaccination", n=97).

Results:

The humoral immune response in the "vaccination" cohort was higher at 3 months, but lower at 10 months, compared to the "infection" cohort due to a faster decline. The "hybrid immunity" cohort had the highest antibody levels at 3 and 10 months with a slower decline compared to the "vaccination" cohort. Surrogate neutralizing antibody levels (expressed as %inhibition of ACE-2 binding) showed a linear relation with log10 of IgG anti-S against WT and four VOC. IgG anti-S corresponding to 90% inhibition ranged from 489 BAU/mL for WT to 1756 BAU/mL for Beta variant. Broad pseudoneutralization predicted live virus neutralization of Omicron BA.1 in 20 randomly selected high titer samples.

Conclusions:

Hybrid immunity resulted in the strongest humoral immune response. Antibodies induced by natural infection decreased more slowly than after vaccination, resulting in higher antibody levels at 10 months compared to vaccinated HCW without prior infection. There was a linear relationship between surrogate neutralizing activity and log10 IgG anti-S for WT and 4 VOC, although some VOC showed reduced sensitivity to pseudoneutralization.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.909910

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.909910